Consolidation EGFR-tyrosine kinase inhibitor (TKI)vs. durvalumab vs. observation in unresectable EGFR-mutant stage III NSCLC Meeting Abstract
| Authors: | Nassar, A. H.; Adib, E.; Kaldas, D.; Feng, J.; AbuAli, T.; Aredo, J.; Fitzgerald, B.; Bar, J.; Thummalapalli, R.; Parikh, K.; Whitaker, R.; Chen, L.; Harris, J.; Ayanambakkam, A.; Farid, S.; Owen, D.; Sharp, J.; Velazquez, A. I.; Ragavan, M.; D'aiello, A.; Cheng, H.; Piotrowska, Z.; Wilgucki, M.; Reuss, J. E.; Patil, T.; Nie, Y.; Baena Espinar, J.; Luders, H.; Grohe, C.; Sankar, K.; Nagasaka, M.; Ashara, Y. P.; Kwiatkowski, D. J.; Mak, R.; Amini, A.; Lobachov, A.; Lin, J. J.; Marron, T.; Yu, H.; Neal, J. W.; Wakelee, H. A.; Shepherd, F. A.; Dilling, T. J.; Gray, J. E.; Naqash, A. R.; Goldberg, S. B.; Kim, S. Y. |
| Abstract Title: | Consolidation EGFR-tyrosine kinase inhibitor (TKI)vs. durvalumab vs. observation in unresectable EGFR-mutant stage III NSCLC |
| Meeting Title: | 2023 World Conference on Lung Cancer (IASLC-WCLC) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 18 |
| Issue: | 11 Suppl. |
| Meeting Dates: | 2023 Sep 9-11 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-11-01 |
| Start Page: | S161 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2023.09.236 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: MA16.11 -- Source: Cinahl |
